Javier Fernández-Ruiz Selected Research

cannabigerol

5/2021	Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's Disease.
1/2021	Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
7/2019	Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.
11/2018	Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis.
1/2018	Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
1/2016	VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Javier Fernández-Ruiz Research Topics

Disease

28	Parkinson Disease (Parkinson's Disease) 12/2021 - 06/2005
23	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 05/2003
22	Huntington Disease (Huntington's Disease) 01/2019 - 04/2002
13	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2021 - 12/2007
11	Disease Progression 01/2021 - 10/2004
9	Multiple Sclerosis 01/2016 - 11/2005
7	Inflammation (Inflammations) 01/2021 - 01/2016
6	Basal Ganglia Diseases (Basal Ganglia Disease) 01/2019 - 01/2006
6	Tremor (Tremors) 06/2012 - 05/2004
5	Alzheimer Disease (Alzheimer's Disease) 03/2021 - 04/2009
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2015 - 11/2005
5	Hypokinesia (Bradykinesia) 12/2009 - 05/2004
4	Atrophy 01/2021 - 01/2006
4	Ataxia (Dyssynergia) 01/2017 - 08/2006
4	Pain (Aches) 11/2015 - 11/2005
4	Gliosis 05/2012 - 10/2006
3	Seizures (Absence Seizure) 01/2022 - 01/2016
3	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2022 - 01/2016
3	Nervous System Diseases (Neurological Disorders) 01/2020 - 01/2006
3	Substance-Related Disorders (Drug Abuse) 01/2019 - 06/2003
3	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2019 - 12/2016
3	Hyperkinesis 07/2005 - 04/2002
2	Febrile Seizures (Febrile Seizure) 01/2022 - 01/2020
2	Paralysis (Palsy) 01/2021 - 06/2015
2	Epileptic Syndromes 01/2020 - 01/2016
2	Dyskinesias (Dyskinesia) 01/2020 - 01/2006
2	Neuroinflammatory Diseases 07/2019 - 02/2013
2	Fibrosis (Cirrhosis) 10/2018 - 02/2016
2	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2018 - 02/2012
2	Alcoholism (Alcohol Abuse) 11/2015 - 07/2015
2	Motor Disorders 03/2014 - 08/2002
2	Schizophrenia (Dementia Praecox) 02/2013 - 06/2010
2	Nausea 02/2013 - 05/2012
2	Vomiting 02/2013 - 05/2012
2	Parkinsonian Disorders (Parkinsonism) 06/2011 - 02/2006
2	Autoimmune Diseases (Autoimmune Disease) 08/2006 - 11/2005
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Hyperglycemia 01/2021
1	Glucose Intolerance 01/2021
1	Arthritis (Polyarthritis) 01/2020
1	Experimental Arthritis 01/2020

Drug/Important Bio-Agent (IBA)

48	CannabinoidsIBA 12/2021 - 04/2002
31	EndocannabinoidsIBA 01/2021 - 04/2002
12	CannabidiolIBA 01/2022 - 02/2007
11	Neuroprotective AgentsIBA 12/2021 - 05/2003
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2010
8	CB2 Cannabinoid ReceptorIBA 11/2021 - 04/2008
7	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2021 - 10/2004
7	EnzymesIBA 01/2018 - 04/2002
6	cannabigerolIBA 05/2021 - 01/2016
6	AntioxidantsIBA 01/2020 - 02/2007
6	nabiximols (Sativex)IBA 03/2017 - 09/2011
5	quinone (benzoquinone)IBA 05/2021 - 03/2015
5	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2020 - 02/2006
5	Cannabinoid Receptor AgonistsIBA 02/2014 - 05/2003
4	Glutamic Acid (Glutamate)FDA Link 11/2018 - 05/2008
4	malonic acid (malonate)IBA 05/2012 - 05/2003
4	Dopamine (Intropin)FDA LinkGeneric 06/2011 - 04/2002
4	RimonabantIBA 05/2008 - 05/2003
4	3-nitropropionic acidIBA 08/2007 - 11/2002
3	LigandsIBA 12/2021 - 11/2005
3	CytokinesIBA 01/2021 - 06/2011
3	gamma-Aminobutyric Acid (GABA)IBA 06/2010 - 04/2002
3	anandamide (arachidonylethanolamide)IBA 10/2006 - 05/2004
2	Sodium Channels (Sodium Channel)IBA 01/2022 - 01/2020
2	Oxidopamine (6 Hydroxydopamine)IBA 05/2021 - 06/2005
2	Calcium Gluconate (CBG)IBA 01/2021 - 07/2019
2	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 01/2006
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 07/2019 - 01/2016
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 07/2019 - 05/2012
2	LipopolysaccharidesIBA 07/2019 - 01/2016
2	Bleomycin (Blenoxane)FDA LinkGeneric 10/2018 - 02/2016
2	Pharmaceutical PreparationsIBA 11/2015 - 05/2012
2	Antineoplastic Agents (Antineoplastics)IBA 03/2015 - 01/2013
2	Transcription Factors (Transcription Factor)IBA 06/2011 - 07/2010
2	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 07/2010 - 04/2002
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 07/2010 - 10/2006
2	alpha-SynucleinIBA 07/2010 - 01/2009
2	ElementsIBA 01/2009 - 04/2008
2	N- (3- furylmethyl)eicosa- 5,8,11,14- tetraenamideIBA 10/2006 - 01/2006
2	N-(4-hydroxyphenyl)arachidonylamide (AM404)IBA 10/2006 - 03/2003
2	N- (2- methyl- 3- hydroxyphenyl)- 5,8,11,14- eicosatetraenamideIBA 10/2006 - 03/2003
2	AmidesIBA 10/2006 - 07/2005
2	arvanilIBA 10/2006 - 07/2005
1	caryophylleneIBA 01/2022
1	NeurotoxinsIBA 12/2021
1	Endoplasmic Reticulum Chaperone BiPIBA 11/2021
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 03/2021
1	SaltsIBA 01/2021
1	CreatinineIBA 01/2021
1	Streptozocin (Streptozotocin)FDA Link 01/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 10/2020
1	DNA-Binding Proteins (DNA Binding Protein)IBA 10/2020
1	AcidsIBA 01/2020
1	Pentylenetetrazole (Metrazol)IBA 01/2020
1	Histones (Histone)IBA 01/2020
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2019

Therapy/Procedure

13	Therapeutics 12/2021 - 12/2009
4	Injections 07/2019 - 11/2002
2	Muscle Denervation 01/2021 - 06/2015